152 related articles for article (PubMed ID: 12647802)
1. Ubiquitinated inclusions and neuronal cell death.
Lang-Rollin I; Rideout H; Stefanis L
Histol Histopathol; 2003 Apr; 18(2):509-17. PubMed ID: 12647802
[TBL] [Abstract][Full Text] [Related]
2. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
Goedert M
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
[TBL] [Abstract][Full Text] [Related]
3. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells.
Rideout HJ; Larsen KE; Sulzer D; Stefanis L
J Neurochem; 2001 Aug; 78(4):899-908. PubMed ID: 11520910
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease.
Liani E; Eyal A; Avraham E; Shemer R; Szargel R; Berg D; Bornemann A; Riess O; Ross CA; Rott R; Engelender S
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5500-5. PubMed ID: 15064394
[TBL] [Abstract][Full Text] [Related]
5. Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination.
Rideout HJ; Stefanis L
Mol Cell Neurosci; 2002 Oct; 21(2):223-38. PubMed ID: 12401444
[TBL] [Abstract][Full Text] [Related]
6. alpha-synuclein is required for the fibrillar nature of ubiquitinated inclusions induced by proteasomal inhibition in primary neurons.
Rideout HJ; Dietrich P; Wang Q; Dauer WT; Stefanis L
J Biol Chem; 2004 Nov; 279(45):46915-20. PubMed ID: 15322100
[TBL] [Abstract][Full Text] [Related]
7. Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders.
Norris EH; Giasson BI
Antioxid Redox Signal; 2005; 7(5-6):672-84. PubMed ID: 15890012
[TBL] [Abstract][Full Text] [Related]
8. Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies.
Ihara M; Tomimoto H; Kitayama H; Morioka Y; Akiguchi I; Shibasaki H; Noda M; Kinoshita M
J Biol Chem; 2003 Jun; 278(26):24095-102. PubMed ID: 12695511
[TBL] [Abstract][Full Text] [Related]
9. Neuropathological spectrum of synucleinopathies.
Jellinger KA
Mov Disord; 2003 Sep; 18 Suppl 6():S2-12. PubMed ID: 14502650
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition.
Rideout HJ; Lang-Rollin IC; Savalle M; Stefanis L
J Neurochem; 2005 Jun; 93(5):1304-13. PubMed ID: 15934949
[TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
12. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia.
Trojanowski JQ; Goedert M; Iwatsubo T; Lee VM
Cell Death Differ; 1998 Oct; 5(10):832-7. PubMed ID: 10203692
[TBL] [Abstract][Full Text] [Related]
13. Synucleins and their relationship to Parkinson's disease.
von Bohlen Und Halbach O
Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
[TBL] [Abstract][Full Text] [Related]
14. Pro-apoptotic protein glyceraldehyde-3-phosphate dehydrogenase promotes the formation of Lewy body-like inclusions.
Tsuchiya K; Tajima H; Kuwae T; Takeshima T; Nakano T; Tanaka M; Sunaga K; Fukuhara Y; Nakashima K; Ohama E; Mochizuki H; Mizuno Y; Katsube N; Ishitani R
Eur J Neurosci; 2005 Jan; 21(2):317-26. PubMed ID: 15673432
[TBL] [Abstract][Full Text] [Related]
15. A Drosophila model of Parkinson's disease.
Feany MB; Bender WW
Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
[TBL] [Abstract][Full Text] [Related]
16. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.
Giasson BI; Duda JE; Quinn SM; Zhang B; Trojanowski JQ; Lee VM
Neuron; 2002 May; 34(4):521-33. PubMed ID: 12062037
[TBL] [Abstract][Full Text] [Related]
17. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
Auluck PK; Chan HY; Trojanowski JQ; Lee VM; Bonini NM
Science; 2002 Feb; 295(5556):865-8. PubMed ID: 11823645
[TBL] [Abstract][Full Text] [Related]
18. [Parkinson's disease: what have we learned from the genes responsible for familial forms?].
Corti O; Brice A
Med Sci (Paris); 2003 May; 19(5):613-9. PubMed ID: 12836396
[TBL] [Abstract][Full Text] [Related]
19. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease.
Chung KK; Zhang Y; Lim KL; Tanaka Y; Huang H; Gao J; Ross CA; Dawson VL; Dawson TM
Nat Med; 2001 Oct; 7(10):1144-50. PubMed ID: 11590439
[TBL] [Abstract][Full Text] [Related]
20. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway.
Lee HJ; Khoshaghideh F; Patel S; Lee SJ
J Neurosci; 2004 Feb; 24(8):1888-96. PubMed ID: 14985429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
